nyuuzyou/wikis huggingface dataset:
Hand-foot syndrome (palmar-plantar erythrodysesthesia) management

==Associated with use of==
*Aldesleukin (Proleukin)
*Capecitabine (Xeloda)
*Cytarabine (Ara-C)
*Doxorubicin (Adriamycin)
*Pegylated liposomal doxorubicin (Doxil)
*Floxuridine (FUDR)
*Fluorouracil (5-FU)
*Idarubicin (Idamycin)
*Ixabepilone (Ixempra)
*Lapatinib (Tykerb)
*Pazopanib (Votrient)
*Sorafenib (Nexavar)
*Sunitinib (Sutent)
*Vemurafenib (Zelboraf)
==Also known as==
Acral erythema, Burgdorf's reaction, hand-foot skin reaction, hand-to-foot syndrome, PPE, toxic erythema of the palms and soles
==References==
# Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs. 2004;8 Suppl 1:S31-40. link to original article PDF of paper at Roche.com EuroPMC
# Mangili G, Petrone M, Gentile C, De Marzi P, Viganò R, Rabaiotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol. 2008 Feb;108(2):332-5. link to original article EuroPMC
# Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008 Sep;13(9):1001-11. Epub 2008 Sep 8. link to original article EuroPMC
# Lacouture, ME. Prevention and Treatment of Multikinase Inhibitor–induced Hand-Foot Syndrome. ASCO Post. December 15, 2012, Volume 3, Issue 18. link to original article
# Management/treatment of Hand-Foot Syndrome or Palmar-Plantar Erythrodysesthesia (Cancer.net)
# Patient education about hand-foot syndrome (Chemocare.com)
# Cutaneous complications of conventional chemotherapy agents (uptodate.com)
# Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy (uptodate.com)
# Prevention and management of hand-foot syndromes (Oncologynurseadvisor.com)
Category:Supportive oncology
HemOnc.org Internship

Our selection process for 2024-2025 has ended; please check back later for next year's opportunities! Below, please see a list of our current and former interns.
=Current interns=
Intern 	Degree(s)	Year 	Position 	Location
Angel LiuLinkedIn	PharmD 	2024-2025	Clinical Oncology Pharmacist	Fred Hutchinson Cancer Center
=Past interns=
Intern 	Degree(s) while intern	Year 	Position while intern 	Location while intern 	Current position 	Current location
Shervin EtemadLinkedIn 	BS 	2019 	Medical student (Y4) 	Vanderbilt University 	Plastic surgery resident 	USC
Zachary MoldwinLinkedIn 	BS 	2019 	PharmD student (Y4) 	UIC 	Clinical Data Science Reviewer 	FDA
Phillip K. MurchLinkedIn	BS 	2020-2021	PharmD student (Y4) 	University of Florida 	District Support Pharmacist 	CVS
Xuanyi (Lexi) Li 	BS 	2021-2022	Medical student (Y4) 	Vanderbilt University 	Hematology/oncology fellow (PGY-4) 	Yale University
Austin FittsLinkedIn 	PharmD 	2021-2022	Pharmacy resident (PGY-1) 	North Mississippi Medical Center 	Surveillance Informatics Fellow 	National Cancer Institute
Linh NguyenLinkedIn 	PharmD, MHSc, MPH 	2021-2022	Pharmacy resident (PGY-2) 	Southern Arizona VA 	Hematology/Oncology Clinical Pharmacist	Phoenix VA
Travis ZackLinkedIn 	MD, PhD 	2022-2023	Hematology/oncology fellow (PGY-5)	UCSF 	Assistant Professor of Medicine 	UCSF
C. Beau Hilton 	MD 	2022-2023	Hematology/oncology fellow (PGY-4)	Vanderbilt University Medical Center	Hematology/oncology fellow (PGY-6) 	Vanderbilt University Medical Center
Sandeep K. JainLinkedIn 	MD 	2023-2024	Hematology/oncology fellow (PGY-6)	Brown University 	Hematology/oncology fellow (PGY-7) 	Brown University
Category:General reference pages
HemOnc.org LLC

HemOnc.org LLC is a Limited Liability Company, incorporated in Massachusetts (2017). The Officers are uncompensated; shares have no monetary value.
=Leadership=
==Chief Executive Officer==
	Peter C. Yang, MDBoston, MA, USA	Dr. Yang is board certified in Hematology and Medical Oncology; he practices at an academically affiliated institution in Massachusetts.
==Chief Technology Officer==
	Jeremy L. Warner, MD, MS, FAMIA, FASCOBrown UniversityProvidence, RI, USALinkedIn	Dr. Warner is board certified in Hematology, Medical Oncology, and Clinical Informatics; he practices at the Lifespan Cancer Institute. He is a Professor of Medicine and Professor of Biostatistics at Brown University. He is the Director of the Brown/Lifespan Center for Clinical Cancer Informatics and Data Science (CCIDS).
Category:Null pages
Hematopoetic progenitor cells, cord blood (Hemacord)

==General information==
Class/mechanism: Hematopoietic stem/progenitor cells isolated from cord blood; hematopoetic progenitor cells, cord blood (HPC-C) migrate to the bone marrow, engraft, divide, and produce mature blood cells. For use in unrelated donor hematopoietic progenitor cell transplantation.Hematopoetic progenitor cells, cord blood (Hemacord) package insertHematopoetic progenitor cells, cord blood (Hemacord) package insert (locally hosted backup)
Route: IV
Extravasation: No information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Patient drug information==
No information available. 
==Also known as==
*Brand name: Hemacord
==References==
Category:Cellular therapy
Category:Intravenous medications
Category:FDA approved in 2011
Hepatic veno-occlusive disease - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main VOD/SOS page for regimens that include active treatment.
=Prophylaxis=
==Observation==
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Corbacioglu et al. 2012 (VOD-DF)	2006-2009 	Phase 3 (C)	Defibrotide	Seems to have higher incidence of VOD by day +30 (primary endpoint)
Grupp et al. 2023 (HARMONY) 	2017-01-11 to 2020-10-20	Phase 3 (C)	Defibrotide	Did not meet primary endpoint of VOD-free survival by day +30
No active treatment.
===References===
#VOD-DF: Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, Boelens JJ, Hewitt A, Schrum J, Schulz AS, Müller I, Stein J, Wynn R, Greil J, Sykora KW, Matthes-Martin S, Führer M, O'Meara A, Toporski J, Sedlacek P, Schlegel PG, Ehlert K, Fasth A, Winiarski J, Arvidson J, Mauz-Körholz C, Ozsahin H, Schrauder A, Bader P, Massaro J, D'Agostino R, Hoyle M, Iacobelli M, Debatin KM, Peters C, Dini G. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012 Apr 7;379(9823):1301-9. Epub 2012 Feb 23. link to original article EuroPMC NCT00272948
#HARMONY: Grupp SA, Corbacioglu S, Kang HJ, Teshima T, Khaw SL, Locatelli F, Maertens J, Stelljes M, Stepensky P, Lopez P, Amber V, Pagliuca A, Richardson PG, Mohty M. Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial. Lancet Haematol. 2023 May;10(5):e333-e345. Epub 2023 Mar 28. Erratum in: Lancet Haematol. 2023 Jul;10(7):e490. link to original article EuroPMC NCT02851407
Category:Hepatic veno-occlusive disease regimens
Category:Disease-specific pages
Category:Null regimens
Heptaplatin (SunPla)

==General information==
Class/mechanism: A second-generation platinum agent with antineoplastic activity.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
*Gastric cancer
==Also known as==
*Code name: SKI-2053R
*Brand name: SunPla
==References==
Category:Drugs
Category:Intravenous medications
Category:Platinum agents
Category:Alkylating agents
Category:Gastric cancer medications
Category:KFDA approved in 1999
Histamine dihydrochloride (Ceplene)

==Mechanism of action==
From Wikipedia: Histamine dihydrochloride acts by improving the immune-enhancing properties of IL-2, and laboratory studies have shown that this combination can induce immune-mediated killing of leukemic cells.
==Also known as==
*Brand name: Ceplene
Category:Drugs
Category:Subcutaneous medications
Category:Immunotherapeutic
Category:Acute myeloid leukemia medications
Category:EMA approved in 2008
Category:Stub
History and physical elements

==Sample elements of a comprehensive visit note==
Chief complaint/reason for visit/admission/consult:
History of present illness:
Review of systems (14-point):
Gen: fatigue, fevers, chills, night sweats, change in appetite, change in weight
Eyes: change in visual acuity, double vision, red eye
ENT: change in hearing, tinnitus, vertigo, ear pain, sinus tenderness, sore throat, congestion, oral ulcers, change in taste, dysphagia, odynophagia
Allergy/immunology: rhinorrhea, sneezing, post-nasal drip
Respiratory: cough, sputum, hemoptysis, shortness of breath, wheezing
Cardiovascular: chest pain/tightness, palpitations, extremity edema, orthopnea, paroxysmal nocturnal dyspnea
GI: nausea, vomiting, diarrhea, constipation, melena, BRBPR, heartburn, stomach ache
GU: incomplete emptying, frequency, starting & stopping, urgency, weak stream, straining to start, nocturia, dysuria, hematuria, incontinence
Dermatology: rash, pruritus, ulcers, jaundice
Hematology/lymph: nose bleed, easy bruising, enlarged nodes
Musculoskeletal: back pain, foot pain, joint stiffness, joint pain, joint swelling
Endo: heat/cold intolerance, excess thirst
Psych: anxiety, insomnia, depression
Neuro: dizziness, fainting, tremor, headache, numbness/tingling, paralysis/weakness, memory changes
Past medical history:
Past surgical history:
Allergies:
Medications:
Family history:
Social history:
Physical exam:
Performance status
General: NAD, alert, appears comfortable
Eyes: PERRL, sclerae anicteric, conjunctivae pink
ENT: OP clear, hearing nl, MMM, no oral ulcers
Neck: supple, thyroid non-tender
CV: RRR, no m/r/g, JVP __ , no carotid bruits, no LE edema, 2+ radials/DP/PT, <2s cap refill, ext WWP
Pulm: BCTA, equal expansion, nl inspiratory effort
Abd: soft, NT, ND, normoactive bowel sounds, no hepatomegaly, no splenomegaly
Skin: no rash, no ulcers, no induration/erythema
Lymph: no cervical, supraclavicular, axillary, inguinal lymphadenopathy
MS: normal muscle tone, no clubbing, no cyanosis
Neuro: fluent speech, oriented to name, place, month/year, intact attention, CNII-XII intact, intact sensation to light touch, 5/5 motor strength, intact reflexes, cerebellar: FNF, RAM, gait
Psych: nl mood & affect, good insight
Labs:
Imaging:
Pathology:
Assessment:
Plan:
Category:General reference pages
Histrelin (Vantas)

==General information==
Class/mechanism: LH-RH agonist. Histrelin acetate inhibits gonadotropin secretion by desensitizing responsiveness of the pituitary gonadotropin which, in turn, causes a reduction in testicular steroidogenesis.Histrelin (Vantas) package insert Histrelin (Vantas) package insert (locally hosted backup)Vantas implant manufacturer's website
Route: SC
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
*Prostate cancer
==History of changes in FDA indication==
*2004-10-12: Initial approval in the palliative treatment of advanced prostate cancer. (Based on Schlegel 2006)
==History of changes in Health Canada indication==
*2006-03-10: Initial notice of compliance (unclear details)
==Patient drug information==
*Histrelin (Vantas) package insert
==Also known as==
*Generic name: histrelin acetate
*Brand names: Supprelin, Vantas
==References==
Category:Drugs
Category:Subcutaneous medications
Category:GnRH agonists
Category:Prostate cancer medications
Category:FDA approved in 2004
Category:Health Canada approved in 2006
How to add HemOnc.org to your home screen

The instructions on this page will show you how to add a convenient shortcut to HemOnc.org to the home screen of your mobile/tablet device. Depending on your preference, you could bookmark the mobile/tablet version of the main page, the regular main page, or any other page that you find to be the most helpful. Please select the device that you have to jump to directions describing the process.
==Android==
This section shows how you can add a shortcut to HemOnc.org to the home screen of your Android device. By doing this, you will be able to access the information on HemOnc.org as conveniently as possible.
===Step 1===
Open the mobile/tablet version of HemOnc.org's main page in your web browser.
===Step 2===
Tap the three dots in the upper right corner to open up the menu, and select "Add to homescreen." On devices such as ones made by Samsung (right), this menu may be accessed with the menu button and appear slightly different.
 
===Step 3===
Type in the name you'd like for this shortcut and click "Add."
 
Congratulations! A shortcut to HemOnc.org is now on your home screen. You can move it around by holding your finger down on it, and then drag the shortcut to whatever place you'd like on your screen.
==iPhone or iPad (iOS)==
This section shows how you can add a shortcut to HemOnc.org to the home screen of your iPhone or iPad. Depending on your version, the screen may look slightly different.
 
By doing this, you will be able to access the information on HemOnc.org as conveniently as possible. 
===Step 1===
Open HemOnc.org in Safari or your preferred iOS/iPhone/iPad web browser, and click the middle button at the bottom of the screen:
 
===Step 2===
Click "Add to Home Screen"
 
===Step 3===
Type in the name you'd like for this shortcut and click "Add" in the upper right corner. The picture on the left may start out as a picture of the page you were on, but will change to the HemOnc.org logo within a few seconds.
 
Congratulations! A shortcut to HemOnc.org is now on your home screen. You can move it around by pressing down on it for several seconds until it starts shaking, and you can then drag the shortcut to whatever place you wish on your screen.
 
Category:General reference pages
How to contribute

==Help wanted!==
If you are a practicing hematology/oncology physician, nurse, advanced practice provider, pharmacist, or other healthcare professional, and you would like to make changes to this website, we'd love to have you on board! We are also open to contributions from healthcare professional trainees. It is easy to learn how to add information, and we'd be happy to set you up for success. Please create an account in the upper right corner, and email contact@hemonc.org to discuss how you'd like to participate. Contributions of all types are welcome, including:
*Chemotherapy regimens--even emailed papers or links to protocols are welcome
*Links to useful resources such as guidelines and online calculators
*Suggestions for supportive care based on personal experience or institutional protocols
*Corrections of typographical or factual errors
*Linking to HemOnc.org from your own blog, Facebook/LinkedIn/Google account, or other website; you can also use the "share" buttons in upper right of most pages for your convenience. Like HemOnc.org on Facebook and join our mailing list.
Once you've signed up for an account, please see the style guide for instructions and guidance on how to contribute in a standardized format. Also see sources to see what primary resources we are using the most often to build and maintain the site.
Check back soon and see what progress is made!
Category:General reference pages
Hydrocortisone (Cortef)

*Steroid conversions
==Diseases for which it is used==
None: only used as a supportive medication.
== Patient Drug Information==
*Hydrocortisone (Cortef) Package InsertHydrocortisone (Cortef) Package Insert
==Also known as==
*Generic names: hydrocortisone sodium phosphate, hydrocortisone sodium succinate
*Brand name: Cortef
==References==
Category:Drugs
Category:Intravenous medications
Category:Intrathecal medications
Category:Steroids
Category:FDA approved in 1983
Category:WHO Essential Cancer Medicine
Hydroxyzine (Atarax)

==General information==
Class/mechanism: first-generation antihistamine.
Route: PO
Extravasation: unknown
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
No known antineoplastic properties. Used for prevention of reactions to blood products or biologics (e.g. monoclonal antibodies) as well as treatment of such reactions.
==Also known as==
*Brand name: Atarax
Category:Drugs
Category:Oral medications
Category:Antihistamines
Category:FDA approved in 1956
Hypercoagulable state (thrombophilia)

==Inherited thrombophilias==
*Prothrombin gene mutation (G20210A)
*Factor V Leiden mutation
*Antithrombin III deficiency
*Protein C deficiency
*Protein S deficiency
*Dysfibrinogenemia
Controversial:
*Plasminogen deficiency
*Factor XII deficiency
==Acquired thrombophilias and clotting risk factors==
*Surgery, foreign bodies such as venous catheters, smoking, obesity, elevated factor VIII, advanced age, male sex, trauma, sedentary state, immobilization, malignancy, myeloproliferative disorders-- polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), pregnancy, medications--e.g. Bevacizumab (Avastin), Lenalidomide (Revlimid), Thalidomide (Thalomid), Tamoxifen (Nolvadex), oral contraceptive use, heparin--in the case of heparin-induced thrombocytopenia/thrombosis (HIT), congestive heart failure, anatomic/low cardiovascular flow states--e.g. inferior vena cava (IVC) abnormalities, chronic inflammation, inflammatory bowel disease, nephrotic syndrome, paroxysmal noctural hemoglobinuria (PNH)
*Prior venous thromboembolism (VTE)
*Antiphospholipid antibody syndrome (APS)
**Lupus anticoagulant: dilute Russell viper venom time (dRVVT), dilute activated partial thromboplastin time (dAPTT), Staclot LA (hexagonal phase phospholipids), Kaolin clotting time (KCT)
**Anticardiolipin (aCL) antibody IgG, IgM, IgA
**Beta 2 glycoprotein 1 (B2GP1) IgG, IgM, IgA
**Sapporo criteria for APS
==Related pages==
*Antiphospholipid antibody syndrome
*Inherited thrombophilia
*Venous thromboembolism
==References==
*Moll S. Thrombophilia: clinical-practical aspects. J Thromb Thrombolysis. 2015 Apr;39(3):367-78. 
**Table of reliability of thrombophilia testing with anticoagulants and in acute thrombosis
Category:Hematology reference pages
Hypereosinophilic syndrome - null regimens

The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main HES page for regimens that include active disease-modifying treatment.
=All lines of therapy=
==Placebo==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Rothenberg et al. 2008 (GSK 100185)	2004-2006 	Phase 3 (C) 	Mepolizumab 	Shorter reduction of the prednisone dose to 10 mg or less per day for 8 or more consecutive weeks (primary endpoint)Endpoint: 43% vs 84%(HR 0.34, 95% CI 0.19-0.63)
Kuang et al. 2019 (NIAID 14-I-0081)	2014-2017 	Randomized Phase 2, fewer than 20 pts (C)	Benralizumab	Seems to have lower reduction of at least 50% in the absolute eosinophil count at week 12 (primary endpoint)Endpoint: 30% vs 90%
No active disease-modifying treatment.
===References===
# GSK 100185: Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008 Mar 20;358(12):1215-28. Epub 2008 Mar 16. Erratum in: N Engl J Med. 2008 Jun 5;358(23): 2530. link to original article EuroPMC NCT00086658
## Update: Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013 Feb;131(2):461-7.e1-5. Epub 2012 Oct 4. link to original article link to PMC article EuroPMC
# NIAID 14-I-0081: Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, Magee T, Piligian B, Yoon P, Ellis JH, Sun X, Panch SR, Powers A, Alao H, Kumar S, Quezado M, Yan L, Lee N, Kolbeck R, Newbold P, Goldman M, Fay MP, Khoury P, Maric I, Klion AD. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med. 2019 Apr 4;380(14):1336-1346. link to original article link to PMC article EuroPMC NCT00001406
Category:Hypereosinophilic syndrome regimens
Category:Disease-specific pages
Category:Myeloproliferative neoplasms
Category:Null regimens
IPH-2101

==General information==
Class/mechanism: Human monoclonal antibody that blocks the interaction of KIR inhibitory receptors on NK (natural killer) cells with their ligands. It is hypothesized that by blocking these inhibitory signals, there will be enhanced activation of NK cells and tumor cell destruction.Innate Pharma's IPH 2101 (Anti-KIR) siteInformation from Innate Pharma about monoclonal antibodies targeting NK cells
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
==Patient drug information==
No information available.
==Also known as==
*Code name: 1-7F9
==References==
Category:Drugs
Category:Intravenous medications
Category:Anti-KIR antibodies
Category:Investigational drugs